publication venue for Real-time evaluation of macozinone activity against Mycobacterium tuberculosis through bacterial nanomotion analysis. 69. 2024 Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis. 68. 2024 Penicillin-binding proteins and alternative dual-beta-lactam combinations for serious Enterococcus faecalis infections with elevated penicillin MICs. 67: e00871-22. 2023 Meropenem plus ceftaroline is active against Enterococcus faecalis in an in vitro pharmacodynamic model using humanized dosing simulations. 66:e00426-22. 2022 First-Time-in-Human Study and Prediction of Early Bactericidal Activity for GSK3036656, a Potent Leucyl-tRNA Synthetase Inhibitor for Tuberculosis Treatment. 63. 2019 Homologous recombination within large chromosomal regions facilitates acquisition of ß-lactam and vancomycin resistance in Enterococcus faecium. 60:5777-5786. 2016 Discovery of novel oral protein synthesis inhibitors of mycobacterium tuberculosis that target leucyl-tRNA synthetase. 60:6271-6280. 2016 Linking murine and human Plasmodium falciparum challenge models in a translational path for antimalarial drug development. 60:3669-3675. 2016 Development of an intracellular screen for new compounds able to inhibit Mycobacterium tuberculosis growth in human macrophages. 60:640-645. 2015 Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs. 59. 2015 Histone methyltransferase inhibitors are orally bioavailable, fast-acting molecules with activity against different species causing malaria in humans. 59:950-959. 2015 Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. 56. 2012 Aminoindoles, a Novel Scaffold with Potent Activity against Plasmodium falciparum. 55:2612-2622. 2011